4basebio Plc Director/PDMR Shareholding
May 11 2022 - 6:57AM
UK Regulatory
TIDM4BB
11 May 2022
4basebio plc
(the "Company")
Director's Dealing
4basebio PLC (AIM: 4BB), the specialist life sciences group focused on
exploiting intellectual property in the field of cell and gene therapies and
DNA vaccines, announces that, on 09 May 2022, Heikki Lanckriet, chief executive
officer, acquired 500 ordinary shares at a price of 500 pence per share.
As a result of the acquisition of ordinary shares, Heikki Lanckriet's
beneficial holding, including shares held by persons closely associated with
him, comprises 1,249,453 ordinary shares representing 10.14 per cent. of the
Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014.
For further enquiries, please contact:
4basebio plc +44 (0)12 2396 7943
Heikki Lanckriet, CEO
Cairn Financial Advisers LLP (Nominated +44 (0)20 7213 0880
Adviser)
Jo Turner / Sandy Jamieson
finnCap Ltd (Broker) +44 (0)20 7220 0500
Geoff Nash/Richard Chambers/Charlotte
Sutcliffe
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1. Details of the person discharging managerial responsibilities/person
closely associated
a. Name Heikki
Lanckriet
2. Reason for notification
a. Position/Status Chief Executive
Officer
b. Initial notification/ Amendment Initial
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name 4basebio plc
b. LEI
213800E2DX9EAIUNCB30
4. Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date; and (iv)
each place where transactions have been conducted
a. Description of the financial instrument, type Ordinary Shares of
instrument
Identification Code ISIN: GB00BMCLYF79
b. Nature of the transaction Acquisition of ordinary
shares
c. Price(s) and volume(s) Volume(s) Price (p)
500 500p
d. Aggregated information
- Aggregated Volume 500
- Price 500 pence per share
e. Date of the transaction 09/05/2022
f. Place of the transaction London Stock Exchange, AIM
END
(END) Dow Jones Newswires
May 11, 2022 06:57 ET (10:57 GMT)
4basebio (LSE:4BB)
Historical Stock Chart
From Apr 2024 to May 2024
4basebio (LSE:4BB)
Historical Stock Chart
From May 2023 to May 2024